BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Astellas Pharma Inc. (YPH.BE)'s Subsidiary Urogenix Inc. Shutting Down, 13 Scientists and Staff Affected


8/6/2012 7:42:42 AM

TOKYO, Aug. 6, 2012 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that it decided to close Urogenix, Inc. ("Urogenix", Durham, NC, President: Shuuichi Tawara), an Astellas subsidiary, which is a research facility focusing on drug discovery in the field of urology. The closure will be completed by the end of December 2012. Urogenix currently employees thirteen scientists and staff.

In March 2006, Astellas acquired this research facility from Dynogen Pharmaceuticals, Inc. Since then, Urogenix has evaluated the clinical potential of urological development candidates especially in the area of lower urinary tract disorders. Urology continues to be one of Astellas' five focus therapeutic areas and upon this decision, Astellas will transfer research functions at Urogenix to Astellas' Tsukuba Research Center in Japan.

The decision to transfer urology research activities to Japan will strengthen the company's commitment to optimizing its research and development resource allocation.

SOURCE Astellas Pharma Inc.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES